Global /Taiwan /Healthcare /Medical Devices /6580

TaiRx, Inc.

6580

• TPEX: 6580 • Delayed

17.60TWD -4.1%

0.5570 USD

As of 7 June 2026, TaiRx, Inc. has a market cap of $65.4M USD, ranking #28614 globally and #1670 in Taiwan. It ranks #2595 in the Healthcare sector, and #533 in the Medical Devices industry.

Global Rank

28614

Country Rank

1670

Sector Rank

2595

Industry Rank

533

Key Stats

Market Cap

$65.4MUSD

2.06B TWD

Enterprise Value

$54.66MUSD

1.73B TWD

Revenue (TTM)

$886.14KUSD

27.88M TWD

EBITDA (TTM)

-$7.36MUSD

-232.62M TWD

Net Income (TTM)

-$7.03MUSD

-221.13M TWD

PS Ratio

73.8

PB Ratio

4.7

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Medical Devices

CEO

Du-Shieng Chien open_in_new

Employees

Founded

2011

Website

trx.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.1%	13%	23%	-15%	-26%	-16%	-28%	-46%	-39%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6580 台睿生物科技股份有限公司 ISIN: TW0006580004 Shares Out.: Shares Outstanding: 112.12M¹ Shares Float: 90.647M² TV: TradingView: TPEX: 6580 SA: Stock Analysis: TPEX: 6580 YF: Yahoo Finance: 6580.TWO GF: Google Finance: TPEX: 6580 BA: Barron's: 6580 MS: Morningstar: ROCO: 6580	17.60 TWD	TV: TradingView: TPEX: 6580 SA: Stock Analysis: TPEX: 6580 YF: Yahoo Finance: 6580.TWO GF: Google Finance: TPEX: 6580 BA: Barron's: 6580 MS: Morningstar: ROCO: 6580

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About TaiRx, Inc.

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. The company was founded in 2011 and is based in Taipei, Taiwan.

Similar Companies

Industry: Medical Devices (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Sunmax Biotechnology Co., Ltd. TPEX: 4728	$670.9M 21.1B TWD 926%	29.1	Taiwan
TaiDoc Technology Corp. TWSE: 4736	$378.99M 11.92B TWD 479%	8.3	Taiwan
YD Bio Ltd. NASDAQ: YDES	$364.92M 458%	-	Taiwan
United Orthopedic Corp. TPEX: 4129	$303.5M 9.55B TWD 364%	17.5	Taiwan
Bioteque Corp. TPEX: 4107	$255.54M 8.04B TWD 291%	15.0	Taiwan
Hi-Clearance Inc. TPEX: 1788	$191.77M 6.03B TWD 193%	16.4	Taiwan

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 265K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 246K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 243K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 193K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 184K%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 156K%	22.2	Ireland

chevron_leftBack